Physician profile
John Baltz
NPI 1861020240
$806.07
in general payments reported to CMS, 2019-2025
18 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $182 · 2024: $441 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $806.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $197.32 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sumitomo Pharma America, INC. | $130.41 | 2023-2024 | Gemtesa |
| Astellas Pharma US INC | $65.32 | 2023-2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.44 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $43.73 | 2024-2025 | Airsupra, Breztri |
| Genzyme Corporation | $43.35 | 2025 | |
| Pfizer INC. | $36.31 | 2024 | |
| Amgen INC. | $30.88 | 2024-2025 | Evenity, Otezla, Repatha |
| Exact Sciences Corporation | $30.26 | 2023-2024 | Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $29.99 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Viatris Specialty LLC | $23.85 | 2025 | Yupelri |
| Boston Scientific Corporation | $22.78 | 2024 | Wavewriter Alpha Prime 16 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.75 | 2024 | Ofev |
| Mylan Specialty L.P. | $22.22 | 2024 | Yupelri |
| Phathom Pharmaceuticals, INC. | $15.46 | 2025 | Voquezna |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $15.22 | 2024 | Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.76 | 2024 | Xifaxan |
| Almatica Pharma LLC | $14.02 | 2024 | Loreev Xr, Teriparatide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Baltz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.